A pediatric multi-system inflammatory syndrome has recently been reported in the United Kingdom and New York City that may be linked to COVID-19. Clinical features of this syndrome have been noted to include features of Kawasaki disease or shock; persistent fever and elevated inflammatory markers (CRP, troponin, etc.) have been seen among affected patients. Reportedly, many of these children have tested positive either for COVID-19 or for its antibodies.
If the above-described inflammatory syndrome is suspected, Arizona providers should immediately:
- Refer patients to a specialist. Appropriate specialties may include pediatric infectious disease, rheumatology, and/or critical care. Early diagnosis and treatment of patients meeting full or partial criteria for Kawasaki disease is critical to preventing end-organ damage and other long-term complications. Patients meeting criteria for Kawasaki disease should be treated with intravenous immunoglobulin and aspirin.
- Consider COVID-19 testing. Many pediatric patients with this syndrome did not show respiratory symptoms, yet tested positive for COVID-19 or its antibodies.
- Report suspected cases of Kawasaki Disease-like Syndrome to local public health. Real-time surveillance of this is critical to public health understanding and recommendations.
The Arizona Department of Health Services and local health departments will continue to monitor developments related to this potentially new syndrome. Please continue to check the ADHS website and the CDC website for the newest, most reliable information. If you have any questions about reporting, please contact your local health department.
Arizona Health Alert Network